Vasculitis and inflammatory arthritis
| Autor: | David G. I. Scott, Richard A. Watts |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Vasculitis
musculoskeletal diseases medicine.medical_specialty Inflammatory arthritis Arthritis Rheumatoid 03 medical and health sciences Psoriatic arthritis 0302 clinical medicine Rheumatology medicine Humans 030212 general & internal medicine Cyclophosphamide Glucocorticoids 030203 arthritis & rheumatology Ankylosing spondylitis business.industry Incidence medicine.disease Dermatology Methotrexate Antirheumatic Agents Rheumatoid arthritis Rheumatoid vasculitis Rituximab business medicine.drug |
| Zdroj: | Best Practice & Research Clinical Rheumatology. 30:916-931 |
| ISSN: | 1521-6942 |
| DOI: | 10.1016/j.berh.2016.10.008 |
| Popis: | Vasculitis has been described in most types of inflammatory arthritis. The best described and most widely recognised form is rheumatoid vasculitis. The incidence of systemic rheumatoid vasculitis has declined significantly following the general early use of methotrexate in the 1990s, and it is now a rare form of vasculitis. Treatment of rheumatoid vasculitis is conventionally with glucocorticoids and cyclophosphamide, but there is an increasing role for rituximab similar to that in other types of vasculitis. Despite these developments the mortality of rheumatoid vasculitis remains high. Vasculitis in other types of inflammatory arthritis is less well described and the treatment remains empirical. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect